CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice.Material and methods. The study included 103 patients with ACS without indications for long-term anticoagulant therapy, which...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Столичная издательская компания 2017-12-01
Rangatū:	Рациональная фармакотерапия в кардиологии
Ngā marau:	acute coronary syndrome pharmacogenetics cyp2c19 clopidogrel ticagrelor clinical guidelines
Urunga tuihono:	https://www.rpcardio.online/jour/article/view/1564
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!